The lysosome as a novel therapeutic target of EGFR-mediated tumor inflammation.

Autor:	Sung WJ; Department of Pathology, Daegu Catholic University School of Medicine, Daegu, South Korea., Kim D; Department of Physiology, Daegu Catholic University School of Medicine, Daegu, South Korea., Zhu A; Department of Physiology, Daegu Catholic University School of Medicine, Daegu, South Korea., Cho N; College of Pharmacy, Chonnam National University, Gwangju, South Korea., Yoo HM; Biometrology Group, Korea Research Institute of Standards and Science, Daejeon, South Korea.; Department of Precision Measurement, University of Science & Technology (UST), Daejeon, South Korea., Noh JH; Department of Biochemistry, Chungnam National University, Daejeon, South Korea., Kim KM; Department of Biological Sciences, Chungnam National University, Daejeon, South Korea., Lee HS; Department of Physiology, Daegu Catholic University School of Medicine, Daegu, South Korea., Hong J; Department of Physiology, Daegu Catholic University School of Medicine, Daegu, South Korea.
Jazyk:	angličtina
Zdroj:	Frontiers in pharmacology [Front Pharmacol] 2022 Nov 11; Vol. 13, pp. 1050758. Date of Electronic Publication: 2022 Nov 11 (Print Publication: 2022).
DOI:	10.3389/fphar.2022.1050758
Abstrakt:	EGFR-mediated tumors have been targeted to overcome several different malignant cancers. EGFR overexpression and mutations are directly related to the malignancy, which makes the therapy more complicated. One reason for the malignancy is the induction of AP1 followed by inflammation via IL-6 secretion. Current therapeutic strategies to overcome EGFR-mediated tumors are tyrosine kinase inhibitors (TKIs), anti-EGFR monoclonal antibodies, and the combination of these two agents with classic chemotherapy or immune checkpoint inhibitors (ICIs). Although the strategies are straightforward and have shown promising efficacy in several studies, there are still hurdles to overcoming the adverse effects and limited efficacy. This study reviews the current therapeutic strategies to target EGFR family members, how they work, and their effects and limitations. We also suggest developing novel strategies to target EGFR-mediated tumors in a novel approach. A lysosome is the main custodial staff to discard unwanted amounts of EGFR and other receptor tyrosine kinase molecules. Targeting this organelle may be a new approach to overcoming EGFR-mediated cancers. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Sung, Kim, Zhu, Cho, Yoo, Noh, Kim, Lee and Hong.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu